Masoumeh Shirmohammadi1, Hoorieh Soleimanjahi1, Zahra Kianmehr2, Hesam Karimi1, Susan Kaboudanian Ardestani3. 1. Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. 2. Department of Biochemistry, Faculty of Biological Science, North Tehran Branch, Islamic Azad University, Tehran, Iran. 3. Immunology Lab, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
Abstract
OBJECTIVES: Human papillomavirus (HPV) is a primary contributing agent of cervical cancer. Eradication of HPV-related infections requires therapeutic strategies. We used Brucella abortus RB51 rough lipopolysaccharide (R-LPS) as an adjuvant along with two HPV16 therapeutic DNA vaccines, pcDNA3-E7 and pcDNA3-L1, for improving DNA vaccine efficacy. MATERIALS AND METHODS: For evaluation of the B. abortus LPS adjuvant efficacy in combination with DNA vaccines to induce cellular immune responses, C57BL/6 mice were immunized with the DNA vaccines, with or without R-LPS adjuvant. IFN-γ and IL-4 cytokines assay was carried out for assessment of cellular and humoral immune responses. RESULTS: Findings indicated that vaccination with pcDNA3-E7 or pcDNA3-L1 alone could induce strong cellular immune responses, but stronger antigen-specific T-cell immune responses were shown by co-administration of HPV16 E7 and HPV16 L1 DNA vaccines along with R-LPS adjuvant. CONCLUSION: Overall, B. abortus R-LPS through enhancement of T-cell immune responses can be considered an efficient vaccine adjuvant in future studies and trials.
OBJECTIVES: Human papillomavirus (HPV) is a primary contributing agent of cervical cancer. Eradication of HPV-related infections requires therapeutic strategies. We used Brucella abortus RB51 rough lipopolysaccharide (R-LPS) as an adjuvant along with two HPV16 therapeutic DNA vaccines, pcDNA3-E7 and pcDNA3-L1, for improving DNA vaccine efficacy. MATERIALS AND METHODS: For evaluation of the B. abortus LPS adjuvant efficacy in combination with DNA vaccines to induce cellular immune responses, C57BL/6 mice were immunized with the DNA vaccines, with or without R-LPS adjuvant. IFN-γ and IL-4 cytokines assay was carried out for assessment of cellular and humoral immune responses. RESULTS: Findings indicated that vaccination with pcDNA3-E7 or pcDNA3-L1 alone could induce strong cellular immune responses, but stronger antigen-specific T-cell immune responses were shown by co-administration of HPV16 E7 and HPV16 L1 DNA vaccines along with R-LPS adjuvant. CONCLUSION: Overall, B. abortus R-LPS through enhancement of T-cell immune responses can be considered an efficient vaccine adjuvant in future studies and trials.
Entities:
Keywords:
Adjuvant; Brucella abortus RB51; Cervical cancer; DNA vaccines; Human papillomavirus; Lipopolysaccharide
Authors: M L De Bruijn; H L Greenstone; H Vermeulen; C J Melief; D R Lowy; J T Schiller; W M Kast Journal: Virology Date: 1998-10-25 Impact factor: 3.616
Authors: Verónica Mata-Haro; Caglar Cekic; Michael Martin; Paula M Chilton; Carolyn R Casella; Thomas C Mitchell Journal: Science Date: 2007-06-15 Impact factor: 47.728